price
CG
NASDAQ · CGTX
Cognition Therapeutics, Inc.
Healthcare · Biotechnology
$0.98
Up+$0.02 (+1.74%)
Updated Sep 11, 2026, 2:27 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 119.2M
- P/E ratio
- -3.13
- Dividend yield
- 0.00%
- 52-week range
- $0.55 – $1.76
- Volume
- 300.39K
- Avg. volume
- 1.86M
Price performance
CGTX price history
1M range · 20 trading sessions · Daily adjusted prices
CGTX closed at $0.98 after 20 trading sessions, down 5.80% for the selected period.
- Last close
- $0.98
- Period change
- -5.80%
- Period low
- $0.96
- Period high
- $1.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $0.99 | $1.005 | $0.97 | $0.9797 | 300.39K |
| Sep 9, 2026 | $1.01 | $1.03 | $0.9864 | $0.99 | 473.92K |
| Sep 8, 2026 | $1.02 | $1.04 | $1.00 | $1.01 | 261.51K |
| Sep 4, 2026 | $1.05 | $1.05 | $1.01 | $1.03 | 377.47K |
| Sep 3, 2026 | $1.05 | $1.06 | $1.02 | $1.05 | 261.51K |
| Sep 2, 2026 | $1.01 | $1.07 | $1.005 | $1.05 | 378.4K |
| Sep 1, 2026 | $1.02 | $1.025 | $0.9815 | $1.01 | 336.78K |
| Aug 31, 2026 | $1.02 | $1.05 | $1.01 | $1.03 | 294.61K |
| Aug 28, 2026 | $1.07 | $1.07 | $1.02 | $1.02 | 347.44K |
| Aug 27, 2026 | $1.07 | $1.08 | $1.04 | $1.06 | 273.37K |
| Aug 26, 2026 | $1.03 | $1.06 | $0.9943 | $1.05 | 466.21K |
| Aug 25, 2026 | $0.9803 | $1.035 | $0.9803 | $1.03 | 416.43K |
| Aug 24, 2026 | $0.99 | $0.9999 | $0.96 | $0.9845 | 249.74K |
| Aug 21, 2026 | $0.975 | $1.01 | $0.9699 | $0.9959 | 308.33K |
| Aug 20, 2026 | $0.9845 | $0.9866 | $0.9301 | $0.9567 | 303.45K |
| Aug 19, 2026 | $0.9942 | $1.02 | $0.961 | $0.9788 | 805.64K |
| Aug 18, 2026 | $1.01 | $1.03 | $0.9816 | $0.9819 | 379.83K |
| Aug 17, 2026 | $1.01 | $1.035 | $1.01 | $1.02 | 434.83K |
| Aug 14, 2026 | $1.04 | $1.0498 | $0.9997 | $1.01 | 509.46K |
| Aug 13, 2026 | $1.03 | $1.0583 | $1.03 | $1.04 | 398.32K |
Latest CGTX news
The latest Smart Investors Daily articles mentioning CGTX.
Stock researchCompany · Financials
Loading stock research…